tbuckley/cabot-search huggingface dataset:
AB0399 SYSTEMIC LUPUS ERYTHEMATOSUS AND OPPORTUNISTIC INFECTIONS: PREVALENCE, FEATURES OF CLINICAL SYMPTOMS
Authors: B. Belov, O. Egorova, D. Movsisyan
Journal: Annals of the Rheumatic Diseases (2020)

Background: Modern therapy for systemic lupus erythematosus (SLE) is associated with long-term treatment with cytotoxic drugs which is often accompanied by activation of comorbid infection, including viral infection. Objectives: to identify prevalence and specific characteristics of the clinical symptoms of co-infection in SLE. Methods: 67 patients with SLE were examined, mainly middle-aged women (62) of 33.5 ± 8.1 years old with the disease duration of 1 to 7 years who received “basic therapy”. All patients were examined by ELISA for the presence of Herpesviridae viruses. Results: In 67 patients, ELISA revealed anti-viral antibodies IgG to CMV (86.5%) and VCA IgG of EBV (56.7%), somewhat less frequently than HSV-1 IgG (38.8%) and HSV-2 (26. 8 %). Active CMV and EBV infections were diagnosed in 26 (38.8%) and 19 (28.3%) patients, respectively; moreover, in 11 patients a combination of production of antibodies of the IgM CMV and EA IgG EBV class was revealed. Analysis of anamnestic data and serological examination allowed us to distinguish 3 groups of patients: group I– 35 patients with a viral infection, including 9 with the infection of a mixed viral and bacterial nature; Group II – 14 patients with bacterial infection and Group III – 18 patients without viral and bacterial complications. Analysis of clinical symptoms showed that there is a definite correlation of high titers of antibodies to CMV and EBV with symptoms such as fever (p&lt;0.01, r=0.74), polyarthralgia (p&lt;0.02, r=0.46) lymphadenopathy (p&lt;0.01, r=0.74), carditis (p&lt;0.05, r=0.42), hepatomegaly (p&lt;0.05, r=0.62), central nervous system damage (p&lt;0.02, r=0.46), migratory erythematous/hemorrhagic rash (p&lt;0.05, r=0.58), urinary syndrome (p&lt;0.02, r=0.41), аnti-dsDNA (p&lt;0.01, r=0.82), ANА (p&lt;0.02, r=0.74); cryoprecipitins (p&lt;0.01, r=0.45). Although there were similar clinical manifestations, the presence of CMV and EBV had some organ specificity. Thus, damage to the central nervous system, joints (polyarthralgia) and liver was more common in patients with CMV, and lymphadenopathy and erythematous/hemorrhagic rash – in patients with EBV. Conclusion: In SLE a comorbid viral infection contributes to clinical picture with a lingering remitting inflammatory process, as well as insufficient effectiveness from corticosteroid and immunosuppressive therapy. Disclosure of Interests: None declared
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis
Authors: Hannah Rosenblum, Ahmad Masri, David L. Narotsky, Jeff Goldsmith, Nadira Hamid, Rebecca T. Hahn, Susheel Kodali, Torsten Vahl, Tamim Nazif, Omar K. Khalique, Sabahat Bokhari, Prem Soman, João L. Cavalcante, Mathew S. Maurer, Adam Castaño
Journal: European Journal of Heart Failure (2020)
Use of facemasks during the COVID-19 pandemic
Authors: Holger J Schünemann, Elie A Akl, Roger Chou, Derek K Chu, Mark Loeb, Tamara Lotfi, Reem A Mustafa, Ignacio Neumann, Lynora Saxinger, Shahnaz Sultan, Dominik Mertz
Journal: The Lancet Respiratory Medicine (2020)
Reply to S.A. Upadhyaya
Authors: Alyssa T. Reddy, Mark D. Krailo, Allen B. Buxton, Douglas R. Strother, Annie Huang, Tianni Zhou, Alexander R. Judkins, Peter C. Burger, Ian F. Pollack, Chris Williams-Hughes, Maryam Fouladi, Ben Ho, Claire M. Mazewski, Victor A. Lewis, Louis-Gilbert Vezina, Timothy N. Booth, Anita Mahajan
Journal: Journal of Clinical Oncology (2020)
Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation
Authors: Elizabeth C. Verna, Marina Serper, Jaime Chu, Kathleen Corey, Oren K. Fix, Karen Hoyt, Kimberly A. Page, Rohit Loomba, Ming Li, Gregory T. Everson, Michael W. Fried, Guadalupe Garcia‐Tsao, Norah Terrault, Anna S. Lok, Raymond T. Chung, K. Rajender Reddy
Journal: Hepatology (2020)

The severe acute respiratory syndrome coronavirus 2 pandemic has drastically altered all facets of clinical care and research. Clinical research in hepatology has had a rich tradition in several domains, including the discovery and therapeutic development for diseases such as hepatitis B and C and studying the natural history of many forms of chronic liver disease. National Institutes of Health, foundation, and industry funding have provided important opportunities to advance the academic careers of young investigators while they strived to make contributions to the field. Instantaneously, however, all nonessential research activities were halted when the pandemic started, forcing those involved in clinical research to rethink their research strategy, including a shift to coronavirus disease 2019 research while endeavoring to maintain their preexisting agenda. Strategies to maintain the integrity of ongoing studies, including patient follow‐up, safety assessments, and continuation of investigational products, have included a shift to telemedicine, remote safety laboratory monitoring, and shipping of investigational products to study subjects. As a revamp of research is being planned, unique issues that face the research community include maintenance of infrastructure, funding, completion of studies in the predetermined time frame, and the need to reprogram career path timelines. Real‐world databases, biomarker and long‐term follow up studies, and research involving special groups (children, the homeless, and other marginalized populations) are likely to face unique challenges. The implementation of telemedicine has been dramatically accelerated and will serve as a backbone for the future of clinical research. As we move forward, innovation in clinical trial design will be essential for conducting optimized clinical research.
The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)
Authors: Ho Sup Lee, Chang-Ki Min, Je-Jung Lee, Kihyun Kim, Sung-Soo Yoon, Inho Kim, Soo-Mee Bang, Jin Seok Kim, Hyeon-Seok Eom, Dok Hyun Yoon, Yoojin Lee, Ho-Jin Shin, Yong Park, Jae-Cheol Jo, Won-Sik Lee, Young Rok Do, Yeung-Chul Mun, Mark Hong Lee, Hyo Jung Kim, Sung-Hyun Kim, Min Kyoung Kim, Sung-Nam Lim, Su-Hee Cho, Seong Kyu Park, Joon-ho Lee, Jae Hoon Lee
Journal: Blood (2017)
Radiotherapy in the era of immunotherapy: teaching an old dog new tricks
Authors: B.C. John Cho, Marc de Perrot
Journal: European Respiratory Journal (2020)

The era of immunotherapy is revolutionising the treatment of solid tumours, as well as shifting the radiotherapeutic paradigm. Radiation that can boost the immune system, with non-ablative doses, provide new and exciting opportunities, such as the ability to generate an in situ vaccination. Specifically, we are interested in effecting a systemic (abscopal) response when combined with immunotherapy, and a durable (vaccinal) response when combined with surgery. Potentiating abscopal and vaccinal effects through combination immunoradiotherapy <https://bit.ly/35Ewzv3>
Abstract 163: Type of Prehospital Airway Management Does Not Affect Chest X-Ray Abnormality in Resuscitated Out-of-Hospital Cardiac Arrest Patients
Authors: Hiromichi Naito, Atsunori Nakao, Alexandra Weissman, Jonathan Elmer, Christian Martin-Gill, Jon C Rittenberger, Francis X Guyette, Elliott K Gozansky, Glenn S Andrews, Clifton W Callaway
Journal: Circulation (2018)

Introduction: Chest x-ray (CXR) abnormalities after cardiopulmonary resuscitation are common. Mechanisms by which these abnormalities develop are not fully elucidated, but aspiration of secretions and regurgitated gastric contents during prehospital airway management may be an important modifiable cause. Hypothesis: We hypothesized that endotracheal intubation (ETI) is associated with decreased incidence of CXR abnormalities after out-of-hospital cardiac arrest (OHCA), as compared to bag-valve-mask (BVM) or supraglottic airway (SGA) use. Methods: We conducted a retrospective review including resuscitated OHCA patients treated at a single academic medical center from 2010-2015. We included patients that had an initial CXR obtained within 66 hours of arrival. We excluded patients with tracheostomy, patients without positive pressure ventilation on emergency department (ED) arrival, or missing initial airway management data. We classified patients by airway management at the time of ED arrival into three groups: BVM, SGA, and ETI. Board certified thoracic imaging radiologists determined if there was any CXR abnormality, and if the observed abnormality was likely due to aspiration. The incidence of any abnormality and aspiration were compared between groups. A multivariable logistic regression model was used to adjust for baseline clinical characteristics. Results: Of the 766 subjects included in the study, 22 (3%) had BVM, 68 (9%) had SGA, and 676 (88%) had ETI. Most 58% were male, 34% had initial rhythm VF/VT, and 61% had a witnessed arrest. Any abnormality on CXR was identified in 543 (71%) cases, and likely aspiration was observed in 205 (27%) cases. Incidence of CXR abnormality was not significantly different between groups: BVM group 18/22 (82%), reference; SGA group 52/68 (76%), OR 0.75, 95% CI 0.13-4.31; ETI group 473/676 (70%), OR 0.81, 95% CI 0.16-4.01. Incidence of aspiration on CXR was also not different between groups: BVM group 6/22 (27%), reference; SGA group 19/68 (28%), OR 1.04, 95% CI 0.18-6.22; ETI group 180/676 (27%), OR 1.26, 95% CI 0.25-6.32. Conclusion: Prehospital airway management strategy for resuscitated OHCA patients was not associated with a significant difference in the incidence of any abnormality or aspiration on CXR.
Pegylated Engineered IL2 plus Anti–PD-1 Monoclonal Antibody: The Nectar Comes from the Combination
Authors: Mathieu Rouanne, Laurence Zitvogel, Aurélien Marabelle
Journal: Cancer Discovery (2020)

In this issue of Cancer Discovery, Diab and colleagues demonstrate in a phase I trial enrolling 38 patients diagnosed with advanced solid tumors that combining the pegylated IL2 bempegaldesleukin with an anti-PD-1 mAb is safe, with an overall response rate of 59.5%. This compelling clinical activity is supported by the potent immune proliferation and activation of circulating T and natural killer cells with a >4-fold increase in the CD8/regulatory T-cell ratio in tumors, independent of baseline PD-L1 expression.See related article by Diab et al., p. 1158.
Abstract 508: Role of Hypoxia Inducible Factor-1 α (HIF-1α) in Plaque Rupture and Survival in ApoE−/SRB − mice
Authors: Mazen K Khalil, Saif Anwaruddin, Feng Dong, Marc S Penn
Journal: Circulation (2008)

Introduction: HIF-1α is an inducible protein stabilized by hypoxia and is thought to be an important mediator of leukocyte metabolism and inflammation. The role of HIF-1α in plaque rupture and acut...
Abstract 17178: Variability in Pacemaker Implantation in the 3M TAVR Study: Indications, Outcomes and Implications
Authors: Janarthanan Sathananthan, John Webb, Dale J Murdoch, Sandra B Lauck, John A Cairns, Karin H Humphries, Richard C Cook, Robert C Welsh, Jonathon Leipsic, Philipp Blanke, Anson Cheung, Jian Ye, Philippe Genereux, Mark Hensey, Madeleine Barker, Benjamin Tyrrell, Faisal Al-Qoofi, James Velianou, Madhu K Natarajan, Harindra C Wijeysundera, Sam Radhakrishnan, Eric Horlick, Mark Osten, Christopher E Buller, Mark D Peterson, Anita W Asgar, Donald Palisaitis, Jean-Bernard Masson, Susheel K Kodali, Tamim Nazif, Vinod H Thourani, Vasilis Babaliaros, David J Cohen, Martin B Leon, David A Wood
Journal: Circulation (2019)

Background: Currently there is no consensus regarding indications and timing of permanent pacemaker implantation (PPI) following transcatheter aortic valve replacement (TAVR). Despite all patients ...
Health and Human Rights: A Call to Action on the 50th Anniversary of the Universal Declaration of Human Rights
Authors: None The Writing Group for the Consortium for Health and Human Rights
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>QuickStats:</i> Age-Adjusted Suicide Rates,*<sup>,†</sup> by State — National Vital Statistics System, United States, 2018
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

2 15.0-19.911.0-14.97.5-10.9DC * Deaths per 100,000 population are age-adjusted to the 2000 U.S. standard population.† As underlying cause of death, suicide is identified with International Classification of Diseases, Tenth Revision codes X60-X84, Y87.0, and also code U03.In 2018, the U.S. suicide rate was 14.2 per 100,000 standard population, with rates varying by state.The five states with the highest age-adjusted suicide rates were Wyoming (25.2),New Mexico (25.0), Montana (24.9),Alaska (24.6), and Idaho (23.9).The five jurisdictions with the lowest suicide rates were the District of Columbia (7.5),New Jersey (8.3),New York (8.3), Rhode Island (9.5), and Massachusetts (9.9).
Secure and Robust Machine Learning for Healthcare: A Survey
Authors: Adnan Qayyum, Junaid Qadir, Muhammad Bilal, Ala Al-Fuqaha
Journal: IEEE Reviews in Biomedical Engineering (2020)

Recent years have witnessed widespread adoption of machine learning (ML)/deep learning (DL) techniques due to their superior performance for a variety of healthcare applications ranging from the prediction of cardiac arrest from one-dimensional heart signals to computer-aided diagnosis (CADx) using multi-dimensional medical images. Notwithstanding the impressive performance of ML/DL, there are still lingering doubts regarding the robustness of ML/DL in healthcare settings (which is traditionally considered quite challenging due to the myriad security and privacy issues involved), especially in light of recent results that have shown that ML/DL are vulnerable to adversarial attacks. In this paper, we present an overview of various application areas in healthcare that leverage such techniques from security and privacy point of view and present associated challenges. In addition, we present potential methods to ensure secure and privacy-preserving ML for healthcare applications. Finally, we provide insight into the current research challenges and promising directions for future research.
Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang<i>et al</i>
Authors: Janine A Lamb, Spyridon Megremis, Hector Chinoy
Journal: Annals of the Rheumatic Diseases (2020)

Mercury (Hg) is increasingly being used as a sedimentary tracer of Large Igneous Province (LIP) volcanism, and supports hypotheses of a coincidence between the formation of several LIPs and episodes of mass extinction and major environmental perturbation. However, numerous important questions remain to be answered before Hg can be claimed as an unequivocal fingerprint of LIP volcanism, as well as an understanding of why some sedimentary records document clear Hg enrichment signals whilst others do not. Of particular importance is evaluating the impact of different volcanic styles on the global mercury cycle, as well as the role played by depositional processes in recording global Hg-cycle perturbations. Here, new mercury records of Cretaceous Oceanic Anoxic Event 2 (OAE 2: ∼94 Ma) and the latest Cretaceous (∼67–66.0 Ma) are presented. OAE 2 is associated with the emplacement of multiple, predominantly submarine, LIPs; the latest Cretaceous with subaerial volcanism of the Deccan Traps. Both of these connections are strongly supported by previously published trends towards unradiogenic osmium- (Os) isotope values in globally distributed sedimentary records. Hg data from both events show considerable variation between different locations, attributed to the effectiveness of different sediment types in registering the Hg signal, with lithologically homogeneous records documenting more clear Hg enrichments than sections with major changes in lithology such as limestones to claystones or organic-rich shales. Crucially, there is no geographically consistent signal of sedimentary Hg enrichment in stratigraphic records of either OAE 2 or the latest Cretaceous that matches Os-isotope evidence for LIP emplacement, indicating that volcanism did not cause a global Hg perturbation throughout the entire eruptive history of the LIPs formed at those times. It is suggested that the discrepancy between Os-isotope and Hg trends in records of OAE 2 is caused by the limited dispersal range of Hg emitted from submarine volcanoes compared to the global-scale distribution of Os. A similar lack of correlation between these two proxies in uppermost Cretaceous strata indicates that, although subaerial volcanism can perturb the global Hg cycle, not all subaerial eruptions will do so. These results highlight the variable impact of different volcanogenic processes on the efficiency of Hg dispersal across the globe. Factors that could influence the impact of LIP eruptions on the global mercury cycle include submarine <i>versus</i> subaerial volcanism, volcanic intensity or explosivity, and the potential contribution of thermogenic mercury from reactions between ascending magma and surrounding organic-rich sediments.
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype
Authors: Barbara Lupo, Francesco Sassi, Marika Pinnelli, Francesco Galimi, Eugenia R. Zanella, Valentina Vurchio, Giorgia Migliardi, Paolo Armando Gagliardi, Alberto Puliafito, Daria Manganaro, Paolo Luraghi, Michael Kragh, Mikkel W. Pedersen, Ivan D. Horak, Carla Boccaccio, Enzo Medico, Luca Primo, Daniel Nichol, Inmaculada Spiteri, Timon Heide, Alexandra Vatsiou, Trevor A. Graham, Elena Élez, Guillem Argiles, Paolo Nuciforo, Andrea Sottoriva, Rodrigo Dienstmann, Diego Pasini, Elena Grassi, Claudio Isella, Andrea Bertotti, Livio Trusolino
Journal: Science Translational Medicine (2020)

Blockade of epidermal growth factor receptor (EGFR) causes tumor regression in some patients with metastatic colorectal cancer (mCRC). However, residual disease reservoirs typically remain even after maximal response to therapy, leading to relapse. Using patient-derived xenografts (PDXs), we observed that mCRC cells surviving EGFR inhibition exhibited gene expression patterns similar to those of a quiescent subpopulation of normal intestinal secretory precursors with Paneth cell characteristics. Compared with untreated tumors, these pseudodifferentiated tumor remnants had reduced expression of genes encoding EGFR-activating ligands, enhanced activity of human epidermal growth factor receptor 2 (HER2) and HER3, and persistent signaling along the phosphatidylinositol 3-kinase (PI3K) pathway. Clinically, properties of residual disease cells from the PDX models were detected in lingering tumors of responsive patients and in tumors of individuals who had experienced early recurrence. Mechanistically, residual tumor reprogramming after EGFR neutralization was mediated by inactivation of Yes-associated protein (YAP), a master regulator of intestinal epithelium recovery from injury. In preclinical trials, Pan-HER antibodies minimized residual disease, blunted PI3K signaling, and induced long-term tumor control after treatment discontinuation. We found that tolerance to EGFR inhibition is characterized by inactivation of an intrinsic lineage program that drives both regenerative signaling during intestinal repair and EGFR-dependent tumorigenesis. Thus, our results shed light on CRC lineage plasticity as an adaptive escape mechanism from EGFR-targeted therapy and suggest opportunities to preemptively target residual disease.
원저 : 만성 B형 간염에서 라미부딘 치료중 발생한 Viral Breakthrough 예의 임상 결과
Authors: 안수현 ( Soo Hyun Ahn ), 장윤정 ( Yun Jung Chang ), 오성남 ( Seong Nam Oh ), 최도원 ( Do Won Choi ), 백수정 ( Soo Jung Baek ), 정원석 ( Won Seok Jeong ), 최창원 ( Chang Won Choi ), 김경오 ( Kyoung Ok Kim ), 임형준 ( Hyung Joon Yim ), 조남영 ( Nam Young Jo ), 박종재 ( Jong Jae B)
Journal: Clinical and Molecular Hepatology (2002)

목적 : 만성 B형 간여의 치료 중 발생하는 약제 내성 변이종은 임상적으로 치료 중 음전되었던 혈청 HBV DNA가 다시 양전되는 viral break-through 로 진단할 수 있다. 현재 약제 내성 변이종이 발생했을 경우라도 라미부딘 치료를 계속 유지 하는 것을 권장하고 있으나, viral breakthrough 발생 예들의 장기적 임상경과가 아직도 불명확하여 이것을 일반화하기는 어려운 상황이다. 이에 라미부딘 사용중 viral breakthrough 가 발생한 예들을 대상으로 그 임상경과를 알아보고자 하였다. 대상과 방법: 9개월 이상 라미부딘을 투약한 만성 B형 간염 환자로 viral breakthrough가 발생한 74명을 대상으로 하였다.(남/여 54/20, 평균연령 42세), viral breakthrough 후 혈청 ALT치, 총 빌리루빈치, HBV DNA 역가, HbeAg, anti-Hbe를 정기적으로 검사하면서 임상경과를 관찰하였다. viral breakthrough후 라미부딘의 투약기간은 평균 13개월 (1-41개월)이었다. 결과: viral breakthrough 발생 후 혈청 ALT치가 정상으로 유지되었던 환자는 8예(11%)에 불과했고 나머지 66예(89%)에서는 ALT치가 증가하였으며, 이중 30예(41%)에서 급성악화(ALT 정상 상한치의 5배 이상 상승)를 보였다. 급서악화는 viral breakthrough 후 3개월 내에 19예(63%)에서 발생하여 3개월 내에 발생한 예가 많았으나 12개월 이상 지나서 나타나는 예도 약 20%에서 있었다. 비대상성 악화는 6예에서 관찰되었다. viral breakthrough 후 급성악화가 일어난 예와 없없던 예의 비교에서 급성악화를 예측할 수 있는 인자는 발견할 수 없었다. viral breakthrough 후 HbeAg이 음전된 예는 8예(11%)였으나 그 임상경과는 양호하지 않았다. 결론: 만성 B형 간염 환자에서 라미부딘 투여 중 발생한 viral breakthrough예 중 상당수에서 급성악화가 발생하였으며, HbeAg이 소실되더라도 그 임상경과는 양호하지만은 않았다. viral breakthrough 발생후 주의깊은 임상경과의 관찰에 요구되며, 앞으로 viral breakthrough 후 급성악화 예에 대한 대규모 연구와 적절한 치료방향의 제시가 이루어져야 할 것으로 생각된다.
Surgery versus cast immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label, randomised superiority trial
Authors: Joseph J Dias, Stephen D Brealey, Caroline Fairhurst, Rouin Amirfeyz, Bhaskar Bhowal, Neil Blewitt, Mark Brewster, Daniel Brown, Surabhi Choudhary, Christopher Coapes, Liz Cook, Matthew Costa, Tim Davis, Livio Di Mascio, Grey Giddins, Helen Hedley, Catherine Hewitt, Sebastian Hinde, Jonathan Hobby, Stephen Hodgson, Laura Jefferson, Kanagaratnam Jeyapalan, Phillip Johnston, Jonathon Jones, Ada Keding, Paul Leighton, Andrew Logan, Will Mason, Andrew McAndrew, Ian McNab, Lindsay Muir, James Nicholl, Matthew Northgraves, Jared Palmer, Rob Poulter, Zulfi Rahimtoola, Amar Rangan, Simon Richards, Gerry Richardson, Paul Stuart, Nicholas Taub, Adel Tavakkolizadeh, Garry Tew, John Thompson, David Torgerson, David Warwick
Journal: The Lancet (2020)
Release of functional fibroblast growth factor-2 from artificial inclusion bodies
Authors: Naroa Serna, Olivia Cano-Garrido, Julieta M. Sánchez, Alejandro Sánchez-Chardi, Laura Sánchez-García, Hèctor López-Laguna, Ester Fernández, Esther Vázquez, Antonio Villaverde
Journal: Journal of Controlled Release (2020)